Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial
Details : This trial is being conducted to evaluate the safety and tolerability of ATG-019 monotherapy or ATG-019 combined with niacin ER, for the treatment of advanced solid tumors or non-Hodgkin's lymphoma.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 13, 2020
LOOKING FOR A SUPPLIER?